<DOC>
	<DOCNO>NCT01435096</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose recommend dose BN80927 patient advance malignant solid tumor .</brief_summary>
	<brief_title>BN80927 Patients With Advanced Malignant Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>All include patient : Gave write ( personally sign date ) inform consent histologically cytologically document malignant solid tumour receive three prior chemotherapy regimen fail standard therapy option active standard therapy estimate survival time great 3 month ( accord investigator 's assessment ) World Health Organisation ( WHO ) performance status score ≤1 free serious concurrent disease adequate bone marrow function adequate liver function adequate renal function female childbearing potential must negative result prestudy pregnancy test βhumanchorionicgonadotrophin ( βHCG ) . No patient include : pregnant lactate unable and/or unwilling comply fully protocol study instruction ; present concomitant condition , could compromise objective study receive investigational drug within 30 day prior study entry schedule require concurrent treatment experimental drug treatment study receive chemotherapy hormonotherapy within 4 week study entry , receive chemotherapy nitrosoureas mitomycinC within 6 week study entry receive extensive palliative curative radiotherapy ( 35 % active bone marrow ) within 2 week study entry , fully recover treatment previously receive bone marrow transplant ( BMT ) peripheral blood progenitor cell ( PBPC ) clinical evidence major organ failure brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>